Lilly sells Zepbound vials from $299/mo: compare 11 direct-pay programs →
Affiliate disclosure: we earn commission from some partners. Learn more.

Compounded tirzepatide in California (2026)

tirzepatide (compounded) · GLP-1 weight management · California

Reviewed by the WeighedHealth Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of July 2026; updated when guidance or availability changes.
Last verified by WeighedHealth Editorial Team against primary sources

About Compounded tirzepatide

Custom-compounded tirzepatide. Cheaper than Zepbound/Mounjaro. Not FDA-approved.

See the full Compounded tirzepatide review for dosing, efficacy data, side effects, and the full pharmacy + telehealth program comparison.

Insurance coverage for Compounded tirzepatide in California

Since January 1, 2026, Medi-Cal Rx no longer covers Wegovy, Zepbound, or Saxenda for weight loss for members 21 and older. Prior authorization is reviewed case by case for Wegovy to treat MASH or reduce cardiovascular risk, and for Zepbound to treat obstructive sleep apnea. Members under 21 can still be reviewed under EPSDT. GLP-1s for type 2 diabetes remain covered.

We do not track carrier-level coverage for Compounded tirzepatide. Check your plan's formulary or our insurance hub.

Telehealth and prescribing in California

A telehealth clinician must be licensed in California to prescribe Compounded tirzepatide to you while you are in California.

Platforms differ in which drugs they prescribe, insurance handling, and clinical model. See our platform comparisons.

Compounded tirzepatide (compounded)

On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

Compounded tirzepatide in California: common questions

Is Compounded tirzepatide legal in California?+

Yes. Compounded tirzepatide (tirzepatide (compounded)) is FDA-approved and legal in all 50 US states including California. State-level differences appear in Medicaid coverage and clinician licensing, not in the legality of the medication itself.

Can I get Compounded tirzepatide via telehealth in California?+

Yes, from a clinician licensed in California. A telehealth clinician must be licensed in California to prescribe Compounded tirzepatide to you while you are in California.

Does California Medicaid cover Compounded tirzepatide?+

Not covered for weight loss. Since January 1, 2026, Medi-Cal Rx no longer covers Wegovy, Zepbound, or Saxenda for weight loss for members 21 and older. Prior authorization is reviewed case by case for Wegovy to treat MASH or reduce cardiovascular risk, and for Zepbound to treat obstructive sleep apnea. Members under 21 can still be reviewed under EPSDT. GLP-1s for type 2 diabetes remain covered.

What's the cheapest way to get Compounded tirzepatide in California?+

The main paths are insurance with prior authorization if your plan covers it, manufacturer cash-pay programs, or telehealth programs that include the medication. NovoCare Pharmacy sells Wegovy pens to cash-pay patients for $349 a month ($199 a month for the first two months for new patients through December 31, 2026). LillyDirect sells Zepbound vials for $299 (2.5 mg), $399 (5 mg), and $449 (7.5 to 15 mg) a month when refilled on time.

Is compounded Compounded tirzepatide still available in California?+

Compounding rules are federal, not set by California. On April 30, 2026, FDA proposed not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list, which would stop outsourcing facilities from compounding them from bulk ingredients. The comment period was extended to July 30, 2026. As of September 15, 2026, no final decision has been published. The proposal does not address 503A compounding for an individual patient's documented clinical need.

Related